Argon plasma coagulation compared with stent placement in the palliative treatment of inoperable oesophageal cancer. Issue 1 (1st February 2017)

• Record Type: Journal Article
• Authors: Sigounas, Dimitrios E; Krystallis, Christoforos; Couper, Graeme; Paterson‐Brown, Simon; Tatsioni, Athina; Plevris, John N
• Is Part Of: United European Gastroenterology journal. Volume 5:Issue 1(2017)
• Page Start: 21
• Page End: 31
• Publication Date: 2017-02-01
• Subjects: Argon plasma coagulation -- self‐expandable metal stents -- oesophageal cancer -- endoscopy -- palliation; Gastroenterology -- Periodicals; Periodicals; 616.33005
• DOI: 10.1177/2050640616650786
• Languages: English
• ISSNs: 2050-6406

Abstract

Abstract : Background: Self‐expandable metal stents (SEMSs) are the main palliative modality used in inoperable oesophageal cancer. Other palliative modalities, including argon plasma coagulation (APC), have also been used. Objective: The purpose of this study was to assess the relative efficacy of SEMS and APC regarding the survival of patients with inoperable oesophageal cancer, not receiving chemo/radiotherapy. Methods: Single centre, retrospective analysis of all patients ( n = 228) with inoperable oesophageal cancer between January 2000 and July 2014, not receiving chemo‐radiotherapy, treated with SEMS ( n = 160) or APC ( n = 68) as primary palliation modalities. Cox regression analysis was performed to identify individual factors affecting survival and Kaplan–Meier curves were created for patients treated with APC and SEMS for stage III and IV disease. Survival intervals were compared by the log‐rank test. Results: Type of treatment was the only statistically significant factor affecting survival, after disease stage stratification (hazard ratio (HR): 1.36, 95% confidence interval (CI): 1.13–1.65 of SEMS over APC, p : 0.002). Median survival for patients treated with APC and SEMS was 257 (interquartile range (IQR): 414, 124) and 151 (IQR: 241, 61) days respectively in stage III disease. It was 135 (IQR: 238, 43) and 70 (IQR: 148, 32) days respectively in stage IV disease. Both differences were statistically significant ( p = 0.02 and 0.05 respectively). Conclusions: APC is a promising palliation modality in inoperable oesophageal cancer, when patients are not candidates for chemo‐radiotherapy. A randomized controlled trial will be needed to confirm those results.